Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTPY4SE)

DTT Name Immunoglobulin Fc receptor (FCR)
Gene Name FCR
DTT Type
Clinical trial target
 [1]
BioChemical Class
Immunoglobulin
UniProt ID
NOUNIPROTAC
TTD ID
T49049

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rozanolixizumab DMK0NGB Generalized myasthenia gravis 8C60 Approved [1]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nipocalimab DM0622O Myasthenia gravis 8C6Y Phase 3 [2]
------------------------------------------------------------------------------------
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
DX-2500 DM3BWTM Ischemic heart disease BA40-BA6Z Investigative [3]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs. 2022 Jun;82(8):865-887.
3 Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Front Immunol. 2015; 6: 176.